Protein biotechnology provides a crucial basis to investigate amyloidogenic proteins and their derived amyloid states. For example, we previously have been using biotechnologically engineered antibody fragments to investigate the mechanism and pathogenicity of different amyloid structures. To that end, we have set up bacterial high cell density fermentation in bioreactors for recombinant protein production. Furthermore, we use a battery of modern high flow rate FPLC systems to purify proteins from small scale to bioprocess scale.